Literature DB >> 17101824

Natural history of human T-lymphotropic virus 1-associated myelopathy: a 14-year follow-up study.

Stéphane Olindo1, Philippe Cabre, Agnes Lézin, Harold Merle, Martine Saint-Vil, Aissatou Signate, Mickael Bonnan, Aurelie Chalon, Lionel Magnani, Raymond Cesaire, Didier Smadja.   

Abstract

BACKGROUND: The progression of neurological disability in human T-lymphotropic virus 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) remains undefined.
OBJECTIVES: To determine the time course of disability scores and to identify predictors of outcome among patients with HAM/TSP.
DESIGN: Clinical 14-year follow-up study.
SETTING: University hospital. Patients One hundred twenty-three patients with HAM/TSP. MAIN OUTCOME MEASURES: We determined time from onset to the following 4 Kurtzke Disability Status Scale (DSS) end points: scores of 6 (unilateral aid required), 6.5 (bilateral aid required), 8 (wheelchair confinement), and 10 (death related to the disease). Times to reach selected DSS scores were estimated using the Kaplan-Meier method. Univariate and multivariate analyses identified variables related to the rate of progression to DSS 8. The HTLV-1 proviral loads were also assessed.
RESULTS: The disability of the cohort progressed throughout the follow-up period. The median times from onset to DSS 6, 6.5, and 8 were 6, 13, and 21 years, respectively. The median time from DSS 6 to DSS 8 was 8 years; DSS 10 was reached by one fourth of the patients within 20 years. Age at onset of 50 years or older and high HTLV-1 proviral load were associated with a shorter time to DSS 8 (P = .01 and P = .02, respectively). A shorter time to DSS 6 significantly adversely affected the time to progression from DSS 6 to DSS 8.
CONCLUSIONS: Human T-lymphotropic virus 1-associated myelopathy/tropical spastic paraparesis is a rapidly disabling disease. Monitoring for HTLV-1 proviral load is recommended in future therapeutic trials.

Entities:  

Mesh:

Year:  2006        PMID: 17101824     DOI: 10.1001/archneur.63.11.1560

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  30 in total

1.  Neurological Manifestations in Human T-Cell Lymphotropic Virus Type 1 (HTLV-1)-Infected Individuals Without HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis: A Longitudinal Cohort Study.

Authors:  Davi Tanajura; Néviton Castro; Paulo Oliveira; Abraão Neto; André Muniz; Natália B Carvalho; Glória Orge; Silvane Santos; Marshall J Glesby; Edgar M Carvalho
Journal:  Clin Infect Dis       Date:  2015-03-27       Impact factor: 9.079

2.  Update on Neurological Manifestations of HTLV-1 Infection.

Authors:  Abelardo Q-C Araujo
Journal:  Curr Infect Dis Rep       Date:  2015-02       Impact factor: 3.725

3.  Isokinetic trunk and knee muscle strengths and gait performance in walking patients with T-cell lymphotropic virus type 1-associated myelopathy/ tropical spastic paraparesis (HAM/TSP).

Authors:  Masashi Miyazaki; Harutoshi Sakakima; Tatsushi Goto; Ryoji Kiyama; Toshio Matsuzaki; Kosei Ijiri; Yoshihiro Yoshida
Journal:  J Jpn Phys Ther Assoc       Date:  2011

4.  Subacute progression of human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis.

Authors:  Marco A Lima; Ramza C Harab; Doris Schor; Maria J Andrada-Serpa; Abelardo Q C Araújo
Journal:  J Neurovirol       Date:  2007-10       Impact factor: 2.643

5.  Early neurologic abnormalities associated with human T-cell lymphotropic virus type 1 infection in a cohort of Peruvian children.

Authors:  Emily A Kendall; Elsa González; Iván Espinoza; Martín Tipismana; Kristien Verdonck; Daniel Clark; Sten H Vermund; Eduardo Gotuzzo
Journal:  J Pediatr       Date:  2009-07-22       Impact factor: 4.406

6.  Increasing utilization of human T-cell lymphotropic virus (+) donors in liver transplantation: is it safe?

Authors:  Michael R Marvin; Guy N Brock; Kwadwo Kwarteng; Ravi Nagubandi; Kadiyala V Ravindra; Mary Eng; Joseph F Buell
Journal:  Transplantation       Date:  2009-04-27       Impact factor: 4.939

7.  HTLV-1-associated myelopathy in a solid organ transplant recipient.

Authors:  Maria Jose Montesdeoca Andrade; Edgar Patricio Correa Diaz; Maria Eugenia Buestán
Journal:  BMJ Case Rep       Date:  2016-06-06

Review 8.  Treatment of HTLV-I-associated myelopathy/tropical spastic paraparesis: toward rational targeted therapy.

Authors:  Unsong Oh; Steven Jacobson
Journal:  Neurol Clin       Date:  2008-08       Impact factor: 3.806

Review 9.  [HTLV-1-associated myelopathy/tropical spastic paraparesis: a differential diagnosis in multiple sclerosis].

Authors:  A Liesz; S Hähnel; K Korn; M Esiri; W Hacke; B Wildemann
Journal:  Nervenarzt       Date:  2012-08       Impact factor: 1.214

10.  Clinical pathophysiology of human T-lymphotropic virus-type 1-associated myelopathy/tropical spastic paraparesis.

Authors:  Yoshihisa Yamano; Tomoo Sato
Journal:  Front Microbiol       Date:  2012-11-09       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.